Phase 3 N=60 Virtual Reality Treatment for Emerging Adults With ADHD
Attention Deficit Hyperactivity Disorder
Primary: Objective On-Task Assessment Algorithm — .86; .62; .83; .83 percentage of time focused
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=29 Tachyphylaxis, Tolerance, & Withdrawal Post Treatment With Igalmi for Agitation in Schizophrenia or Bipolar Disorder
Bipolar Disorder · Schizophrenia · Agitation,Psychomotor
Primary: Change From Baseline in the Positive and Negative Syndrome Scale- Excited Component (PEC) Total Score — -10.4; -10.0; -10.1; -9.8 score on a scale
N/A N=128 A Smartphone-Based Intervention to Improve Colorectal Cancer Screening in African American Men
Colorectal Cancer
Primary: Percentage of Participants Who Received a Colorectal Cancer Screening Test — 2; 2 Participants
Phase 4 N=124 Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema Trial
Moderate-to-Severe Atopic Dermatitis · Atopic Eczema
Primary: Percentage of Participants With ≥75% Reduction From Baseline in Eczema Area and Severity Index (EASI) Score (EASI-75) — 76.0 percentage of participants
N/A N=74 Performance and Safety of T2769 Versus Hylo-Forte® in the Treatment of Moderate to Severe Dry Eye Syndrome.
Dry Eye Syndrome
Primary: To Demonstrate the Non-inferiority of T2769 Compared to Hylo-Forte® in Terms of Total Ocular Surface Staining (Oxford Score). — -1.3; -1.2 score on a scale
Phase 2 N=159 Efficacy and Safety Assessment of T4090 Ophthalmic Solution Versus Rhopressa® Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension
Glaucoma · Ocular Hypertension
Primary: Mean Diurnal IOP — -5.07; -4.73; -4.6 mmHg — p=0.376
Phase 3 N=151 Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY II)
Agitation · Dementia
Primary: Absolute Change From Baseline in Positive and Negative Syndrome Scale- Excited Component (PEC) Total Score for the First Episode of Agitation — -5.7; -7.5; -5.4 score on…
Phase 2 N=35 Heart Failure Polypill at a Safety Net Hospital
Heart Failure With Reduced Ejection Fraction · HIV Infections
Primary: Measured Adherence to GDMT by Pill Count — 74.6; 83.3 adherence ratio expressed in %
N/A N=3,017 A Study to Learn About Novel Hormonal Therapies in People With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
Prostatic Neoplasms
Primary: Duration of NHT Treatment — 11.9 Months
N/A N=116 VIdeo Telehealth in ALzheimer's: NeuroPsychology (VITAL-NP)
Suspected Typical Alzheimer's Disease (AD) · Suspected Atypical Alzheimer's Disease (AD)
Primary: Agreement of Cognitive Test Results Across Testing Modalities as Measured by Neuropsychological Test Mean Scores, Measures With Total Correct Items — 4.31; 4.40; 8.21…
N/A N=386 Sperm Selection by Microfluidic Separation Improves Embryo Quality
Sperm DNA Fragmentation · Embryo Quality · Fertility Disorders
Primary: Day 3 High Quality Embryo Percentage — 68; 66 percentage of high quality embryos
Phase 3 N=305 A Study of the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia.
Schizophrenia
Primary: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Events (AEs) Leading to Study Discontinuation — 153; 77; 16; 0 Participants
N/A N=106 Validation of Naevia Medical in Valvulopathies
Heart Valve Disease
Primary: Number of Relevant Appropriate Recommendations — 2.35; 6.20 Recommendations
Phase 4 N=10 Influence of Anesthetic Technique on Acute and Chronic Neuropathic Pain
Acute Pain · Chronic Pain · Hernia
Primary: Pain Score, Chronic — 1.7; 1.5; 0; .8 score on a scale
Phase 3 N=877 An Extension Study of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis
Ulcerative Colitis
Primary: Number of Participants Experiencing Treatment-Emergent Adverse Event (TEAEs) — 139; 160; 342; 37 Participants